Aegera Therapeutics Inc. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 48
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: AB019C03E8DEN
Leaflet:

Download PDF Leaflet

Aegera Therapeutics Inc. - Product Pipeline Review - Q4 2010
Aegera Therapeutics Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Aegera Therapeutics Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Aegera Therapeutics Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Aegera Therapeutics Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Aegera Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Aegera Therapeutics Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Aegera Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Aegera Therapeutics Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Aegera Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Aegera Therapeutics Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Aegera Therapeutics Inc. and identify potential opportunities in those areas.
Aegera Therapeutics Inc. Snapshot
Aegera Therapeutics Inc. Overview
Key Information
Key Facts
Aegera Therapeutics Inc. – Research and Development Overview
Key Therapeutic Areas
Aegera Therapeutics Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Aegera Therapeutics Inc. – Pipeline Products Glance
Aegera Therapeutics Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Aegera Therapeutics Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Aegera Therapeutics Inc. – Drug Profiles
AEG33773
  Product Description
  Mechanism of Action
  R&D Progress
AEG35156
  Product Description
  Mechanism of Action
  R&D Progress
AEG35156 + Ara-C + Idarubicin
  Product Description
  Mechanism of Action
  R&D Progress
AEG35156 + Paclitaxel
  Product Description
  Mechanism of Action
  R&D Progress
AEG35156 + Sorafenib
  Product Description
  Mechanism of Action
  R&D Progress
AEG40826
  Product Description
  Mechanism of Action
  R&D Progress
AEG41174
  Product Description
  Mechanism of Action
  R&D Progress
AEG35156
  Product Description
  Mechanism of Action
  R&D Progress
AEGXXXXX
  Product Description
  Mechanism of Action
  R&D Progress
Aegera Therapeutics Inc. – Pipeline Analysis
Aegera Therapeutics Inc. – Pipeline Products by Therapeutic Class
Aegera Therapeutics Inc. Pipeline Products By Target
Aegera Therapeutics Inc. – Pipeline Products by Molecule Type
Aegera Therapeutics Inc. - Dormant Projects
Aegera Therapeutics Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Jul 19, 2010: Aegera Reports Survival Data From Phase I Portion Of Phase I- II Study Of AEG35156 In Combination With Sorafenib
Jan 26, 2010: Aegera Therapeutics Initiates Phase 2 Study Of AEG35156 For The Treatment Of Hepatocellular Carcinoma
Nov 23, 2009: Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial Of Lead IAP Inhibitor HGS1029 In Advanced Lymphoid Tumors
May 06, 2009: Aegera Initiates Phase 2 Clinical Trial Of AEG33773
Jan 08, 2009: Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study Of AEG35156 For 1st Line Treatment Of Non-Small Cell Lung Cancer
Jul 31, 2008: Aegera Initiates A Fifth Phase 1 And 2 Clinical Trial For AEG35156
Jun 10, 2008: Aegera Therapeutics Collaboration With Human Genome Sciences Leads To The Initiation Of A Phase 1 Clinical Trial With Lead IAP Inhibitor HGS1029 And Receipt Of First Milestone Payment
Jun 10, 2008: Aegera Therapeutics Collaboration With Human Genome Sciences Leads To The Initiation Of A Phase 1 Clinical Trial With Lead IAP Inhibitor HGS1029 And Receipt Of First Milestone Payment
May 30, 2008: Human Genome Sciences Initiates First Clinical Trial Of Lead IAP Inhibitor HGS1029 In Advanced Solid Tumors
Mar 18, 2008: Aegera Initiates Phase I Clinical Trial Of AEG33773
Financial Deals Landscape
Aegera Therapeutics Inc., Deals Volume Summary, 2004 to YTD 2010
Aegera Therapeutics Inc., Deals Summary By Region, 2004 to YTD 2010
Aegera Therapeutics Inc., Deals Summary, 2004 to YTD 2010
Aegera Therapeutics Inc. Detailed Deal Summary
Venture Financing
Aegera Therapeutics Secures $12.21 Million In Series C Financing
Aegera Therapeutics Secures $15 Million In Series B Financing
Licensing Agreements
Neurologix Signs Licensing Agreement With Aegera Therapeutics
Human Genome Sciences Enters Into Licensing Agreement With Aegera Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 48

LIST OF TABLES

Aegera Therapeutics Inc. – Pipeline by Therapy Area and Indication, 2010
Aegera Therapeutics Inc. – Pipeline by Stage of Development, 2010
Aegera Therapeutics Inc. – Monotherapy Products in Pipeline, 2010
Aegera Therapeutics Inc. – Combination Treatment Modalities in Pipeline, 2010
Aegera Therapeutics Inc. - Phase II, 2010
Aegera Therapeutics Inc. - Phase I, 2010
Aegera Therapeutics Inc. - Pipeline By Therapeutic Class, 2010
Aegera Therapeutics Inc. - Pipeline By Target, 2010
Aegera Therapeutics Inc. – Pipeline By Molecule Type, 2010
Aegera Therapeutics Inc. - Dormant Developmental Projects, 2010
Aegera Therapeutics Inc., Deals Summary, 2004 to YTD 2010
Aegera Therapeutics Inc., Deals Summary by Region, 2004 to YTD 2010
Aegera Therapeutics Inc., Deals Summary, 2004 to YTD 2010
Aegera Therapeutics Secures $12.21 Million In Series C Financing
Aegera Therapeutics Secures $15 Million In Series B Financing
Neurologix Signs Licensing Agreement With Aegera Therapeutics
Human Genome Sciences Enters Into Licensing Agreement With Aegera Therapeutics 45

LIST OF FIGURES

Aegera Therapeutics Inc. – Pipeline by Therapy Area and Indication, 2010
Aegera Therapeutics Inc. – Pipeline by Stage of Development, 2010
Aegera Therapeutics Inc. – Monotherapy Products in Pipeline, 2010
Aegera Therapeutics Inc. – Combination Treatment Modalities in Pipeline, 2010
Aegera Therapeutics Inc. – Pipeline By Therapeutic Class, 2010
Aegera Therapeutics Inc. - Pipeline By Target, 2010 26

Ask Your Question

Aegera Therapeutics Inc. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: